Nautilus Medical has announced delivery of their robust image management platform with all features to any medical professionals and students at no cost.

To Meet Burgeoning Need, RCA Adds a Third Center in New Jersey for Life-Saving Addiction Treatment Services

Leading Provider of Post-Acute Care Forms Component Patient Safety Organization

Research from the American Cancer Society shows lung cancer rates in Asian-Americans vary among subgroups.

Researchers from the University of California San Diego (UC San Diego) and its School of Medicine have completed a study that may help to better understand treatments and preventions for diseases affecting memory.

Updated Phase 3 ALCYONE results, featured as oral presentation at ASH 2018, show improved progression-free survival in newly diagnosed patients

Novartis announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL), respectively.

University of California (UC) San Diego Health has named San Diego Padres and San Diego Sea Lions soccer team physician Dr. Catherine Robertson as chief of sports medicine.

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for the treatment of Pancreatic Cancer. OBI-888 is a first in class monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Patients at Hunt Regional Medical Center in Greenville, Texas can now access industry leading interactive features on their patient-room televisions, thanks to the hospital’s launch this month of Allen Technologies’ E3 Patient Engagement Solution.

American Academy of Orthopaedic Surgeons issued the following announcement on Nov. 16.A new review article published in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds arthroscopic (joint replacement or reconstruction) management could be a promising option for young, active patients diagnosed with GHOA.

The University of Pittsburgh Medical Center's (UPMC) Hillman Cancer Center recently became the first cancer center in western Pennsylvania to offer immunotherapy for non-Hodgkin lymphoma cancer patients.

Pioneers in reproductive medicine to recruit patients for clinical trial of new method of testing embryos for chromosome abnormalities

Guidelines focus on lifestyle and behavioral management, pharmacologic approaches, and strategies for avoiding and treating diabetes-related complications

A new study shows that inhaled insulin is successful to treat Type 1 diabetes.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued a narrated scientific white paper titled: “The critical importance of selectivity when developing antibody therapies for Alzheimer’s disease.”

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF), for the treatment of pulmonary alveolar proteinosis (PAP).

Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's New Drug Application (NDA) for ALKS 5461.

The U.S. Food and Drug Administration permitted marketing of two devices that provide real-time location of parathyroid tissue during surgical procedures such as thyroidectomy (surgery to remove all or part of the thyroid) and parathyroidectomy (surgery to remove one or more parathyroid glands).